NASDAQ: $SOPH
SOPHiA GENETICS, a recognized leader in AI-driven precision medicine, has significantly augmented its presence in the United States through agreements with two substantial, integrated healthcare systems. This expansion marks a pivotal moment in bringing advanced genomic analysis to a wider patient population across key regions.
These two newly integrated institutions represent some of the largest analytical centers in U.S. healthcare. One is a prominent nonprofit, multi-region integrated system, and the other is ranked among the top 10 U.S. health system laboratories. Collectively, these organizations process millions of genetic samples annually. Their adoption of the SOPHiA DDM™ platform—an AI-native, cloud-based solution—will facilitate the analysis of large volumes of complex genomic data efficiently.
Accelerating Diagnosis and Personalized Care
The immediate impact of this collaboration will be felt by patients on the West Coast and in the Midwest. The two health systems are set to initiate genomic testing for an estimated 60,000 patients each year. This enhanced capability is designed to provide quicker diagnoses and facilitate more personalized treatment strategies for individuals dealing with hereditary cancers and rare diseases.
Central to this integration is the utilization of SOPHiA DDM™ for its Enhanced Exome application. This powerful, AI-driven analytics tool supports comprehensive analysis of the entire exome, encompassing over 20,000 genes. Crucially, it allows analysts to focus with precision on clinically significant regions of the genome. By embedding these advanced analytical capabilities directly into their established laboratory operations, the health systems anticipate reducing testing turnaround times, optimizing operational expenditures, and bolstering internal capabilities for research and innovation.
A Scalable Foundation for Future Precision Medicine
John Carey, Managing Director for North America at SOPHiA GENETICS, highlighted the significance of these partnerships. “Collaborating with two of the nation’s largest health systems validates the increasing requirement for genomic solutions powered by artificial intelligence that can manage increasingly intricate use cases while remaining scalable without creating additional operational strain,” stated Carey. “By integrating advanced bioinformatics, the aggregated knowledge of our worldwide community, and optimized workflows, our AI empowers healthcare organizations to derive more profound insights.”
This collaboration establishes a robust, scalable framework for both organizations to support the future growth of AI-driven precision medicine. Annually, these institutions collectively serve nearly one million patients nationwide who are managing cancer and rare disorders.
SOPHiA GENETICS continues to solidify its position within the United States market, offering support to leading healthcare providers navigating some of the most demanding challenges in precision medicine. This expansion reaffirms the company’s commitment to making data-driven medicine more accessible by providing researchers and clinicians with AI-powered tools that accelerate innovation and advancement in healthcare.